For diabetes-induced nerve damage (neuropathies) caused byvitamin B1 deficiency
Treatment of neuropathies and cardiovascular disorders that are caused by vitamin B1 deficiency. Proven therapeutic indications for mono-preparations are exclusively treatment or prophylaxis of clinical vitamin B1 deficiencies, that cannot be corrected through a healthy diet.
One tablet contains benfotiamine (lipid-soluble vitamin B1 derivative) 300 mg.Benfotiamine
The tablets are best to be taken by swallowing without chewing with sufficient fluid.
The duration of administration is determined by the therapeutic response.
For the treatment of neuropathies, milgamma® protekt tablets should be taken initially over a period of at least 3 weeks.
Afterwards maintenance treatment in accordance with therapeutic response. If no efficacy or a too slight efficacy is recognizable after 4 weeks, the treatment of the complaints should be examined.
milgamma® protekt. Active substance: Benfotiamine. Therapeutic indications: Treatment of neuropathies and cardiovascular disorders that are caused by vitamin B1 deficiency. If you have any questions about risks and side effects, please read the patient information leaflet and ask your doctor or pharmacist. WÖRWAG Pharma GmbH & Co. KG, 71034 Böblingen